Purple biotech highlights significant advantages of the novel captn-3 tri-specific antibody platform at the eacr 2025 annual congress

Rehovot, israel, june 23, 2025 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel captn-3 tri-specific antibody platform in a poster presentation at the 2025 annual congress of the european association for cancer research (eacr 2025), that was held in lisbon, portugal from june 16-19, 2025.
PPBT Ratings Summary
PPBT Quant Ranking